Special unlicensed medicines: what we do and do not know about them.

Do We Know What We Do not Know? A Response to Celine Bonnet

Diagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?

What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.

Travel Diarrhea in Childhood “First Part; what do we know?”

Molecular approaches to diagnosis of invasive aspergillosis what we know and what we do not know.

Invasive aspergillosis (IA) are a major complication in immunocompromized patients where can be serious and rapidly fatal. Early diagnosis and early appropriate antifungal treatment is important in reducing mortality and morbidity. But despite many efforts to develop detection methods, the diagnosis of IA still remains challenging and current conventional methods are limited for adequate diagno...

High Stakes Require More Than Just Talk: What to Do About Corruption in Health Systems; Comment on “We Need to Talk About Corruption in Health Systems”

Reluctance to talk about corruption is an important barrier to action. Yet the stakes of not addressing corruption in the health sector are higher than ever. Corruption includes wrongdoing by individuals, but it is also a problem of weak institutions captured by political interests, and underfunded, unreliable administrative systems and healthcare delivery models. We ur...